Latest News and Press Releases
Want to stay updated on the latest news?
-
LUND, Sweden, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced that a biomarker trend analysis of overall survival (OS) and Progression Free Survival...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Detaljerad analys ger ytterligare stöd åt...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Detailed analysis further supports effect of...
-
LUND, Sweden, Sept. 5, 2013 (GLOBE NEWSWIRE) -- Lund, Sweden, September 5, 2013 - Active Biotech (NASDAQ OMX NORDIC: ACTI) is scheduled to present at the Rodman & Renshaw Annual Global Investment...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund den 5 september 2013 - Active Biotech...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund, Sweden, September 5, 2013 - Active...
-
For release content, please refer to the attachment....
-
For release content, please refer to the attachment....
-
Events during January - June 2013: Laquinimod · positive results from Phase IIa study of laquinimod in active lupus nephritis· Teva plans continued clinical development of laquinimod for the...
-
Händelser under januari - juni, 2013: Laquinimod · positiva resultat från fas IIa-studie av laquinimod i aktiv lupus nefrit· Teva planerar fortsatt klinisk utveckling av laquinimod för behandling av...